Market capitalization | $168.90m |
Enterprise Value | $-59.27m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.37 |
P/B ratio (TTM) P/B ratio | 0.60 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-183.58m |
Free Cash Flow (TTM) Free Cash Flow | $-158.98m |
Cash position | $239.44m |
As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.
8 Analysts have issued a Ventyx Biosciences forecast:
8 Analysts have issued a Ventyx Biosciences forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.39 -1.39 |
153%
153%
|
|
EBITDA | -182 -182 |
8%
8%
|
EBIT (Operating Income) EBIT | -184 -184 |
8%
8%
|
Net Profit | -171 -171 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Raju Mohan |
Employees | 80 |
Founded | 2018 |
Website | www.ventyxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.